Historical Archive
This press release was originally distributed via the eWire press wire service (2002–2016). It is preserved here as a historical record.
Proliant Inc. Debuts New Manufacturing Facility for the Expanded Production of ImmunoLinâ¢
ARCHIVED 2002–2016: Originally distributed via the eWire press wire service. Preserved as historical record.
Proliant Inc. Debuts New Manufacturing Facility for the Expanded Production of ImmunoLinâ¢
SUBSCRIBE/UNSUBSCRIBE |
Conservation & Wildlife
Corporate Responsibility
Science & Technology
Syndication Partners
**************************************************************************
E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE
**************************************************************************
For Immediate Release
Proliant Inc. Debuts New Manufacturing Facility for the Expanded Production of ImmunoLinâ¢
AMES, IOWA, May. 1 -/E-Wire/-- Proliant Inc. announced the completion of a state-of-the-art manufacturing plant for the production of its immunoglobulin isolate, ImmunoLinâ¢. This plant makes Proliant the first company to offer commercial quantities of purified immunoglobulin (IgG), a specialized protein produced by the immune system, to the nutrition industry. ImmunoLinâ¢, marketed by the Health Division of Proliant Inc., is a non-dairy product that delivers a consistent concentration of immunoglobulin and other immunoproteins. This new ingredient creates the potential for new products and the enhancement of existing formulations in the expanding immune product segment of the nutrition industry. Proliant's Health Division specializes in providing new ingredients to the dietary supplement and nutrition industries.
"This plant utilizes the best-available protein separation technology with years of experience in the food industry in the production of ImmunoLinâ¢. The debut of our new manufacturing plant underscores our commitment to the development of new, high-quality proteins for the nutrition industry." commented Keith Barnes, President and CEO of Proliant Inc.
The GMP plant utilizes food-grade USDA-approved raw materials and features a highly automated, closed loop system that isolates raw material and production from sources of variability and contamination. Total control over raw material collection and transport completes this "closed loop" system that enhances product consistency and addresses the tougher regulatory standards needed by the industry.
ImmunoLin⢠contains a minimum IgG content of 45% versus 15% to 20% for colostrum and contains a natural balance of growth factors. "ImmunoLin⢠fills the void in the immune product segment for a cost-effective passive immunity ingredient with unprecedented purity. Based on our successful experiences in other markets, we believe the demand by the nutraceutical market for passive immunity ingredients is going to explode in the years ahead as the industry learns more about these proteins." emphasizes Eric Weaver, Ph.D., Director of Proliant Health.
About Proliant Proliant Inc. is a leading innovator in applied protein sciences. Proliant Ingredients serves the food industry including the dairy, bakery, nutrition, snack, meat/savory and prepared foods markets. Proliant Biologicals serves the diagnostic, life science research, biopharmaceutical and veterinary vaccine markets. Proliant Health serves the health and nutrition industry, including the dietary supplement, clinical nutrition, consumer health and functional food markets. Wilke Resources is the exclusive U.S. sales and marketing agent for ImmunoLinâ¢. Call [REDACTED-PHONE] or email [REDACTED-EMAIL] for additional information on ImmunoLinâ¢.
**************************************************************************
To Transmit Your News Over E-Wire, visit http://www.ewire.com or
call 1-[REDACTED-PHONE]. E-Wire Is Broadcast To Millions Of Readers Worldwide
**************************************************************************
1993 - 2003. All Rights Reserved.